Patient-centered drug discovery is at the core of what we do at Curemark. We approach neurological disorders from a translational and innovative perspective.
Our technology focuses on the role of amino acids in neurological diseases. Amino acids are known to play a role in protein synthesis, CNS gene regulation and the formation of key neurotransmitters, such as serotonin and dopamine. The exocrine pancreas produces enzymes which digest food, including protein. The enzymatic protein breakdown results in a balanced amino acid pool. Enzymatic deficiencies, such as the one we have identified in Autism, may play a key role in the etiology of the disease.
To target patients’ unique needs, Curemark has required an entirely new approach to delivering its products. Our technology masks taste, has a smooth, indistinguishable texture in the mouth and most importantly, allows for optimal release in the proper portion of the small intestine.